Cyclic peptide compositions for treatment of sexual dysfunction

Details Cyclic peptide compositions for treatment of sexual dysfunction Cyclic peptide compositions for treatment of sexual dysfunction

2011-03-01

2011-03-01

Kam, Chih-Min (Department: 1656)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

Cyclic peptides

C530S300000, C530S328000, C530S329000, C514S009100, C514S011400, C514S016700, C514S017400

Reexamination Certificate

active

07897721

ABSTRACT:
A cyclic peptide of the structural formula:or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, m and p are as defined. Further provided are compositions for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction, by administration of a cyclic peptide including a C-terminus —OH group. Routes of administration include injection, oral, urethral, vaginal, nasal and mucosal administration.

REFERENCES:
patent: 3853836 (1974-12-01), Greven
patent: 3862928 (1975-01-01), De Wied et al.
patent: 4649191 (1987-03-01), Hruby
patent: 4696913 (1987-09-01), Geiger et al.
patent: 5420109 (1995-05-01), Suto et al.
patent: 5576290 (1996-11-01), Hadley
patent: 5674839 (1997-10-01), Hruby et al.
patent: 5693608 (1997-12-01), Bechgaard et al.
patent: 5714576 (1998-02-01), Hruby et al.
patent: 5731408 (1998-03-01), Hadley et al.
patent: 5908825 (1999-06-01), Fasano et al.
patent: 5977070 (1999-11-01), Piazza et al.
patent: 6051555 (2000-04-01), Hadley
patent: 6054556 (2000-04-01), Hruby et al.
patent: 6534503 (2003-03-01), Dines et al.
patent: 6579968 (2003-06-01), Blood et al.
patent: 6794489 (2004-09-01), Blood et al.
patent: 7176279 (2007-02-01), Sharma et al.
patent: 7342089 (2008-03-01), Sharma et al.
patent: 7473760 (2009-01-01), Sharma et al.
patent: 2001/0056179 (2001-12-01), Chen et al.
patent: 2002/0004512 (2002-01-01), Bakshi et al.
patent: 2003/0083228 (2003-05-01), Carpino et al.
patent: 2691465 (1993-11-01), None
patent: 2735131 (1996-12-01), None
patent: WO-94/22460 (1994-10-01), None
patent: WO-99/21571 (1999-05-01), None
patent: WO-99/41156 (1999-08-01), None
patent: WO-99/43709 (1999-09-01), None
patent: WO-99/55679 (1999-11-01), None
patent: WO-99/57148 (1999-11-01), None
patent: WO-99/64002 (1999-12-01), None
patent: WO-00/53148 (2000-09-01), None
patent: WO-00/74679 (2000-12-01), None
patent: WO-01/00224 (2001-01-01), None
patent: WO-01/05401 (2001-01-01), None
patent: WO-01/10842 (2001-02-01), None
patent: WO-02/26774 (2002-04-01), None
patent: WO-03/006604 (2003-01-01), None
patent: WO-03/006620 (2003-01-01), None
Bednarek, Maria A., et al., “Structure-function studies on the cyclic peptide MT-II, lactam derivative of a-melanotropin”, Peptides, vol. 20,(1999),401-409.
Benelli, A. , et al., “Oxytocin Enhances, and Oxytocin Antagonism Decreases, Sexual Receptivity in Intact Female Rats”, Neuropeptides, vol. 27,(1994),245-250.
Brandenburger, et al., “Synthesis and Receptor Binding Analysis of Thirteen Oligomeric a-MSH Analogs”, J. of Receptor & Signal Transduction Research, 19(1-4),(1999),467-480.
Donlon, John , “The Production of Biologically Active Peptides in Brain Tissues”, Metabolism of Brain Peptides, Edited by Gerard O'Cuinn, PhD,(1995),1-9.
Grant, Gregory A., “Protein and Amino Acid Chemistry”, Synthetic Peptides: A User's Guide, Washington University School of Medicine,(1992),11-24.
Hadley, Mac E., et al., “Melanocortin Receptors: Identification and Characterization by Melanotropic Peptide Agonists and Antagonists”, Pigment Cell Res, vol. 9,(1996),213-234.
Haskell-Luevano, et al., “Discovery of Prototype Peptidomimetic Aganists at the Human Melanocortin Receptors MC1R and MC4R”, Journal Medical Chemistry, V. 40,(1997) 2133-2139.
Hruby, Victor J., et al., Cyclic Lactam a-Melanotropin Analogues of Ac-Nle(4)-cyclo[Asp (5),D-Phe(7), Lys(10) a-Melanocyte-Stimulating Hormone-(4-10)-NH(2) with Bulky Aromatic.
Amino Acids at Position 7 show high Antagonist Potency and Selectivity at Specific Melanocortin Receptors, Journal of Medical Chemistry, vol. 38,(1995),3454-3461.
Hruby,et al., “Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical”, Biocheistry, J., V268,(1990),249-262.
Low, Miklos , et al., “Role of Chain Termini in Selective Steroidogenic Effect of ACTH/MSH(4-10) on Isolated Adrenocortical Cells”, Peptides, vol. 11,(1990),29-31.
Merrifield, Robert B., “Solid Phase Synthesis (Nobel Lecture)”, Angewandte Chemie, vol. 24, No. 10,(Oct. 1985),799-892.
O'Cuinn, Gerard , et al., “Neuropeptide Inactivation by Peptidases”, Metabolism of Brain Peptides, Edited by Gerard O'Cuinn, Ph.D.,(1995),99-101.
Schioth, Helgi B., et al., “Discovery of novel melanocortin(4) receptor selective MSH analogues”, British Journal of Pharmacology, vol. 124,(1998),75-82.
Schioth, Helgi B., et al., “Selective properties of C- and N-terminals and core residues of the melanocyte-stimulating hormone on binding to the human melanocortin receptor subtypes”, European Journal of Pharmacology, vol. 349,(1998),359-366.
Toniolo, C. , “Conformationally restricted peptides through short-range cyclizations”, Int. J. Peptide Protein Res., vol. 35,(1990),287-300.
Wessells, H. , et al., “Synthetic Melanotropic Peptide Initiates Erections in Men with Psychogenic Erectile Dysfunction: Double-Blind, Placebo Controlled Crossover Study”, The Journal of Urology, vol. 160(2),(Aug. 1998),389-393.

Affiliated with

Also associated with

Rating

Cyclic peptide compositions for treatment of sexual dysfunction does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclic peptide compositions for treatment of sexual dysfunction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic peptide compositions for treatment of sexual dysfunction will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2709050